Modified immune cells for blood cancers after chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have one of these blood cancers: acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) that has returned or not responded to at least two treatments.
- You have a specific genetic marker called HLA-A*02:01 (a blood test can check this).
- You are well enough to carry out daily activities (Karnofsky score more than 50%).
- Your heart, lungs, kidneys, and liver are working reasonably well, as shown by tests.
- You are not pregnant, and if you can have children, you agree to use effective birth control during and for a few months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests a new treatment using specially engineered immune cells (NK cells) that target the CD5 protein found on certain T-cell blood cancers. The cells are given after a short course of chemotherapy to help them work better. It may be an option for people with aggressive T-cell cancers that have not responded to standard therapy.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Hear when a new Lymphodepleting Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.